Effect of beinaglutide treatment on weight loss in Chinese patients with type 2 diabetes mellitus and overweight/obesity

ABSTRACT Objective: To evaluate the effect of beinaglutide on weight loss and plasma protein patterns of inflammation/obesity relevant cytokines and biomarkers. Materials and methods: This study involved 36 adult patients with a body mass index (BMI) of ≥ 24 kg/m2 and T2DM. Beinaglutide was administered for three months. Changes in body weight, fasting plasma glucose (FPG) level, 2 h postprandial plasma glucose (2h-PG) level, glycosylated hemoglobin (HbA1c) level, BMI and visceral and subcutaneous fat areas were measured at baseline and after three months of treatment. In addition, relevant inflammation/obesity cytokines and biomarkers were measured. Results: After three months, beinaglutide treatment led to significant changes, including in body weight, BMI, FPG level, HbA1c level, visceral and subcutaneous fat areas. In addition, serpin E1, leptin, C-reaction protein (CRP) and tumor necrosis factor-α (TNF-α) also decreased significantly. The plasma protein concentrations of CRP (Log2 transformed) were found to be positively correlated with the percentage of weight loss (R = 0.514 and p-value = 0.021). Conclusion: Beinaglutide treatment resulted in weight loss, plasma glucose control and anti-inflammatory effects in patients with T2DM and overweight/obesity.

Effect of beinaglutide treatment on weight loss in Chinese patients with type 2 diabetes mellitus and overweight/obesity.

OBJECTIVE: To evaluate the effect of beinaglutide on weight loss and plasma protein patterns of inflammation/obesity relevant cytokines and biomarkers. METHODS: This study involved 36 adult patients with a body mass index (BMI) of ≥ 24 kg/m2 and T2DM. Beinaglutide was administered for three months. Changes in body weight, fasting plasma glucose (FPG) level, 2 h postprandial plasma glucose (2h-PG) level, glycosylated hemoglobin (HbA1c) level, BMI and visceral and subcutaneous fat areas were measured at baseline and after three months of treatment. In addition, relevant inflammation/obesity cytokines and biomarkers were measured. RESULTS: After three months, beinaglutide treatment led to significant changes, including in body weight, BMI, FPG level, HbA1c level, visceral and subcutaneous fat areas. In addition, serpin E1, leptin, C-reaction protein (CRP) and tumor necrosis factor-α (TNF-α) also decreased significantly. The plasma protein concentrations of CRP (Log2 transformed) were found to be positively correlated with the percentage of weight loss (R = 0.514 and p-value = 0.021). CONCLUSION: Beinaglutide treatment resulted in weight loss, plasma glucose control and anti-inflammatory effects in patients with T2DM and overweight/obesity.

Scutellaria barbata polysaccharides inhibit tumor growth and affect the serum proteomic profiling of hepatoma H22­bearing mice.

The present study aimed to evaluate the antitumor effect of Scutellaria barbata polysaccharides (SBPS) in a hepatoma mouse model and examine the serum proteins involved in the tumorigenesis and SBPS treatment. A hepatoma model was established by the subcutaneous inoculation of murine hepatocellular carcinoma into Kunming mice. The treatment (once a day) lasted until the tumor weight in the model group was ~1 g (~7­10 days after inoculation). The sera proteins from each group were then collected and subjected to two­dimensional gel electrophoresis. Differentially expressed proteins were screened out and representatives were identified using matrix­assisted laser desorption ionization time­of­flight mass spectrometry. SBPS treatment at different doses significantly inhibited hepatoma growth (all P<0.01 vs. model group). The comparative serum proteomics showed that pseudouridine synthase 1 and chain A of the signal recognition particle Alu RNA­binding heterodimer (Srp9/14) were increased in the serum of the H22 hepatoma­bearing mice, and both were reduced by SBPS treatment. Mitochondrial ribosomal protein L24 was absent from the serum of H22 hepatoma­bearing mice, and was restored by SBPS treatment to approximately the normal level. Taken together, SBPS inhibited the growth of hepatic carcinoma in mice and affected serum proteomic profiling.